Powerful findings in Christian Hendershot's RCT w/ 48 non-treatment seekers and relatively low doses of semaglutide.| recursiveadaptation.com
“I’m now offering GLP-1s to nearly all my substance use disorder patients.”| recursiveadaptation.com
A unique opportunity for a breakthrough in medicine and public health| recursiveadaptation.com
The FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.| U.S. Food and Drug Administration
Why does the United States put so few resources into developing new medical treatments for drug abuse when the ongoing financial, social, and medical costs of addiction are so shockingly high?| recursiveadaptation.com
Dr.| recursiveadaptation.com
GLP-1s or obesity drugs are growing in popularity. What does this mean for sectors ranging from biotech to insurance and food?| www.jpmorgan.com
We can restructure science funding to help breakthrough research translate more quickly| Institute for Progress
– Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized controlled trials – – Treatment with VX-548 was also shown to be effective in...| Vertex Pharmaceuticals Newsroom
Some medicine for type 2 diabetes can improve blood sugar control and also may support weight loss.| Mayo Clinic
Operation Warp Speed was a federal effort that supported multiple COVID-19 vaccine candidates to speed up development. We analyzed the program's...| www.gao.gov
Map and trend line show provisional national counts and state-level percent changes in overdose deaths—updated monthly| www.cdc.gov